Intravenous thrombolysis with low-dose recombinant tissue plasminogen activator in acute ischemic stroke

Stroke

Volumn 41, Issue 3, 2010, Pages

  Loh, Pei Kee ^a   Sharma, Vijay K ^a  

^a NATIONAL UNIVERSITY HOSPITAL   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE;

ACUTE DISEASE; ASIA; BLEEDING; BLOOD CLOT LYSIS; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; CLINICAL RESEARCH; DRUG SAFETY; HEALTH CARE COST; HEALTH SERVICE; HUMAN; JAPANESE; LETTER; LOW DRUG DOSE; NEUROIMAGING; PRIORITY JOURNAL; RACE DIFFERENCE;

ASIAN CONTINENTAL ANCESTRY GROUP; BRAIN ISCHEMIA; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; INFUSIONS, INTRAVENOUS; MALE; RECOMBINANT PROTEINS; STROKE; TISSUE PLASMINOGEN ACTIVATOR;

EID: 77649108041     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/STROKEAHA.109.573113     Document Type: Letter

References (8)

1. Toyoda K, Koga M, Naganuma M, Shiokawa Y, Nakagawara J, Furui E, Kimura K, Yamagami H, Okada Y, Hasegawa Y, Kario K, Okuda S, Nishiyama K, Minematsu K. Stroke Acute Management with Urgent Risk-factor Assessment and Improvement Study Investigators. Routine use of intravenous low-dose recombinant tissue plasminogen activator in Japanese patients: general outcomes and prognostic factors from the SAMURAI Register. Stroke. 2009;40:3591-3595.
2. Poungvarin N. Stroke in the developing world. Lancet. 1998;352(suppl III):19-22. (Pubitemid 128643741)
3. Ueshima S, Matsuo O. The differences in thrombolytic effects of administrated recombinant t-PA between Japanese and Caucasians. Thromb Haemost. 2002;87:544-546.
4. Yamaguchi T, Mori E, Minematsu K, Nakagawara J, Hashi K, Saito I, Shinohara Y. Japan Alteplase Clinical Trial (J-ACT) Group. Alteplase at 0.6 mg/kg for acute ischemic stroke within 3 hours of onset: Japan Alteplase Clinical Trial (J-ACT). Stroke. 2006;37:1810-1815.
5. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333:1581-1587.
6. Sharma VK, Tsivgoulis G, Tan JH, Ong BKC, Chan BPL, Teoh HL. Feasibility and safety of intravenous thrombolysis in multiethnic Asian stroke patients in Singapore. J Stroke Cerebrovasc Dis. In press.
7. Suwanwela NC, Phanthumchinda K, Likitjaroen Y. Thrombolytic therapy in acute ischemic stroke in Asia: the first prospective evaluation. Clin Neurol Neurosurg. 2006;108:549-552.
8. Padma MV, Singh MB, Bhatia R, Srivastava A, Tripathi M, Shukla G, Goyal V, Singh S, Prasad K, Behari M. Hyperacute thrombolysis with IV rtPA of acute ischemic stroke: efficacy and safety profile of 54 patients at a tertiary referral center in a developing country. Neurol India. 2007;55: 46-49.